{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:51:56Z","timestamp":1786362716747,"version":"build-2736575974"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,1,27]],"date-time":"2005-01-27T00:00:00Z","timestamp":1106784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,1,27]],"date-time":"2005-01-27T00:00:00Z","timestamp":1106784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2005,3,1]]},"DOI":"10.1038\/sj.jhh.1001807","type":"journal-article","created":{"date-parts":[[2005,1,27]],"date-time":"2005-01-27T11:31:18Z","timestamp":1106825478000},"page":"185-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antithrombotic therapy in hypertension: a Cochrane Systematic review"],"prefix":"10.1038","volume":"19","author":[{"given":"D C","family":"Felmeden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Y H","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,1,27]]},"reference":[{"key":"BF1001807_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/oxfordjournals.bmb.a072892","volume":"50","author":"R Collins","year":"1994","unstructured":"Collins R, MacMahon S . Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272\u2013298.","journal-title":"Br Med Bull"},{"key":"BF1001807_CR2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","volume":"335","author":"R Collins","year":"1990","unstructured":"Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827\u2013838.","journal-title":"Lancet"},{"key":"BF1001807_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/0140-6736(90)90878-9","volume":"335","author":"R Collins","year":"1990","unstructured":"Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765\u2013774.","journal-title":"Lancet"},{"key":"BF1001807_CR4","doi-asserted-by":"crossref","unstructured":"Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903\u20131913.","DOI":"10.1016\/S0140-6736(02)11911-8"},{"key":"BF1001807_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1046\/j.1365-2796.2001.00800.x","volume":"249","author":"GYH Lip","year":"2001","unstructured":"Lip GYH, Edmunds E, Beevers DG . Should patients with hypertension receive antithrombotic therapy? J Intern Med 2001; 249: 205\u2013214.","journal-title":"J Intern Med"},{"key":"BF1001807_CR6","first-page":"693","volume":"8","author":"GYH Lip","year":"1994","unstructured":"Lip GYH, Beevers DG . Abnormalities of rheology and coagulation in hypertension. J Hum Hypertens 1994; 8: 693\u2013702.","journal-title":"J Hum Hypertens"},{"key":"BF1001807_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/sj.jhh.1000556","volume":"11","author":"AJ Lee","year":"1997","unstructured":"Lee AJ . The role of rheological and haemostatic factors in hypertension. J Hum Hypertens 1997; 11: 767\u2013776.","journal-title":"J Hum Hypertens"},{"key":"BF1001807_CR8","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1097\/00004872-199609002-00016","volume":"14","author":"PM Vanhoutte","year":"1996","unstructured":"Vanhoutte PM . Endothelial dysfunction in hypertension. J Hypertens Suppl 1996; 14: S83\u2013S93.","journal-title":"J Hypertens Suppl"},{"key":"BF1001807_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1161\/01.CIR.101.3.218","volume":"101","author":"GY Lip","year":"2000","unstructured":"Lip GY, Blann AD . Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation 2000; 101: 218\u2013220.","journal-title":"Circulation"},{"key":"BF1001807_CR10","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/S0002-9149(97)00749-2","volume":"80","author":"GYH Lip","year":"1997","unstructured":"Lip GYH et al. Relationship of endothelium, thrombogenesis, and haemorrheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997; 80: 1566\u20131571.","journal-title":"Am J Cardiol"},{"key":"BF1001807_CR11","volume-title":"Cochrane Library","author":"JB Segal","year":"2001","unstructured":"Segal JB et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter (Cochrane Review). In: Cochrane Library, Issue 2. Update Software: Oxford, 2001 CD001938."},{"key":"BF1001807_CR12","doi-asserted-by":"crossref","unstructured":"SPAF II Study. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687\u2013691.","DOI":"10.1016\/S0140-6736(94)91577-6"},{"key":"BF1001807_CR13","volume-title":"The Cochrane Library","author":"GYH Lip","year":"2001","unstructured":"Lip GYH, Gibbs CR . Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm (Cochrane Review). In: The Cochrane Library, Issue 4. John Wiley & Sons, Ltd: Chichester, UK, 2001 CD003333."},{"key":"BF1001807_CR14","doi-asserted-by":"crossref","unstructured":"WHO\u2013ISHGMH. World Health Organization\u2013International Society of Hypertension Guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151\u2013183.","DOI":"10.1097\/00004872-199917020-00001"},{"key":"BF1001807_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/sj.jhh.1000917","volume":"13","author":"L Ramsay","year":"1999","unstructured":"Ramsay L et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569\u2013592.","journal-title":"J Hum Hypertens"},{"key":"BF1001807_CR16","doi-asserted-by":"crossref","unstructured":"WHO Guidelines Sub-Committee. Guidelines for the management of mild hypertension: memorandum from a World Health Organization\/International Society of Hypertension meeting. J Hypertens 1993; 11: 905\u2013918.","DOI":"10.1097\/00004872-199309000-00004"},{"key":"BF1001807_CR17","volume-title":"The Cochrane Library, Issue 2","author":"M Clarke","year":"2003","unstructured":"Clarke M, Oxman AD (eds). Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]. In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software."},{"key":"BF1001807_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.7326\/0003-4819-126-5-199703010-00008","volume":"126","author":"CD Mulrow","year":"1997","unstructured":"Mulrow CD, Cook DJ, Davidoff F . Systematic reviews: critical links in the great chain of evidence. Ann Intern Med 1997; 126: 389\u2013391.","journal-title":"Ann Intern Med"},{"key":"BF1001807_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/bmj.321.7252.13","volume":"321","author":"TW Meade","year":"2000","unstructured":"Meade TW, Brennan PJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000; 321: 13\u201317.","journal-title":"BMJ"},{"key":"BF1001807_CR20","doi-asserted-by":"crossref","unstructured":"The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233\u2013241.","DOI":"10.1016\/S0140-6736(97)11475-1"},{"key":"BF1001807_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0002-9149(01)01735-0","volume":"88","author":"CM O'Connor","year":"2001","unstructured":"O'Connor CM et al. Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). Am J Cardiol 2001; 88: 541\u2013546.","journal-title":"Am J Cardiol"},{"key":"BF1001807_CR22","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/NEJMoa011258","volume":"345","author":"JP Mohr","year":"2001","unstructured":"Mohr JP et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444\u20131451.","journal-title":"N Engl J Med"},{"key":"BF1001807_CR23","doi-asserted-by":"crossref","unstructured":"The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857\u2013865.","DOI":"10.1002\/ana.410420606"},{"key":"BF1001807_CR24","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1161\/01.CIR.103.25.3069","volume":"103","author":"T Huynh","year":"2001","unstructured":"Huynh T et al. Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001; 103: 3069\u20133074.","journal-title":"Circulation"},{"key":"BF1001807_CR25","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1016\/S0735-1097(01)01285-2","volume":"37","author":"H Schuhlen","year":"2001","unstructured":"Schuhlen H et al. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol 2001; 37: 2066\u20132073.","journal-title":"J Am Coll Cardiol"},{"key":"BF1001807_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/hj.1999.v137.92521","volume":"137","author":"MC Thel","year":"1999","unstructured":"Thel MC et al. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. Am Heart J 1999; 137: 264\u2013273.","journal-title":"Am Heart J"},{"key":"BF1001807_CR27","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1161\/01.CIR.97.19.1912","volume":"97","author":"NS Kleiman","year":"1998","unstructured":"Kleiman NS et al. Diabetes mellitus, glycoprotein IIb\/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 1998; 97: 1912\u20131920.","journal-title":"Circulation"},{"key":"BF1001807_CR28","first-page":"169","volume":"15","author":"S Novo","year":"1996","unstructured":"Novo S et al. Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. Int Angiol 1996; 15: 169\u2013174.","journal-title":"Int Angiol"},{"key":"BF1001807_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000204871","volume":"85","author":"C Finelli","year":"1991","unstructured":"Finelli C et al. Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors. A double-blind controlled study. Acta Haematol 1991; 85: 113\u2013118.","journal-title":"Acta Haematol"},{"key":"BF1001807_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJM198908243210804","volume":"321","author":"WK Hass","year":"1989","unstructured":"Hass WK, et al., for the Ticlopidine Aspirin Stroke Study Group. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501\u2013507.","journal-title":"N Engl J Med"},{"key":"BF1001807_CR31","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment randomised trial. Lancet 1998; 351: 1755\u20131762.","journal-title":"Lancet"},{"key":"BF1001807_CR32","doi-asserted-by":"crossref","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329\u20131339.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"BF1001807_CR33","doi-asserted-by":"crossref","unstructured":"Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy\u2014I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81\u2013106.","DOI":"10.1136\/bmj.308.6921.81"},{"key":"BF1001807_CR34","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJM200005043421803","volume":"342","author":"WW O'Neill","year":"2000","unstructured":"O'Neill WW et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of oral xemilofiban in controlling thrombotic events. N Engl J Med 2000; 342: 1316\u20131324.","journal-title":"N Engl J Med"},{"key":"BF1001807_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0266462300009557","volume":"12","author":"K Dickersin","year":"1996","unstructured":"Dickersin K, Herxheimer A . Introduction: the quality of the medical evidence: is it good enough? Int J Technol Assess Health Care 1996; 12: 187\u2013189.","journal-title":"Int J Technol Assess Health Care"},{"key":"BF1001807_CR36","unstructured":"Lefebvre C, McDonald S . Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Paper presented at the Fourth International Cochrane Colloquium, Adelaide, Australia, 20\u201324 October 1996."},{"key":"BF1001807_CR37","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/01.CIR.102.5.500","volume":"102","author":"UA Ajani","year":"2000","unstructured":"Ajani UA et al. Alcohol consumption and risk of coronary heart disease by diabetes status. Circulation 2000; 102: 500\u2013505.","journal-title":"Circulation"},{"key":"BF1001807_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1067\/mhj.2000.108239","volume":"140","author":"DL Bhatt","year":"2000","unstructured":"Bhatt DL et al. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000; 140: 67\u201373.","journal-title":"Am Heart J"},{"key":"BF1001807_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/01.CIR.103.3.363","volume":"103","author":"DL Bhatt","year":"2001","unstructured":"Bhatt DL et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001; 103: 363\u2013368.","journal-title":"Circulation"},{"key":"BF1001807_CR40","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1161\/01.CIR.101.19.2231","volume":"101","author":"RM Califf","year":"2000","unstructured":"Califf RM et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 2000; 101: 2231\u20132238.","journal-title":"Circulation"},{"key":"BF1001807_CR41","first-page":"1720","volume":"10","author":"F Caravaca","year":"1995","unstructured":"Caravaca F et al. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. Nephrol Dial Transplant 1995; 10: 1720\u20131724.","journal-title":"Nephrol Dial Transplant"},{"key":"BF1001807_CR42","first-page":"1137","volume":"24","author":"ME Cook","year":"1997","unstructured":"Cook ME et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 1997; 24: 1137\u20131144.","journal-title":"J Rheumatol"},{"key":"BF1001807_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/08037059209077512","volume":"1","author":"JR Cusson","year":"1992","unstructured":"Cusson JR et al. Effect of ketoprofen on blood pressure, endocrine and renal responses to chronic dosing with captopril in patients with essential hypertension. Blood Press 1992; 1: 162\u2013167.","journal-title":"Blood Press"},{"key":"BF1001807_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jama.1972.03210050013003","volume":"222","author":"A Drapkin","year":"1972","unstructured":"Drapkin A, Merskey C . Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. JAMA 1972; 222: 541\u2013548.","journal-title":"JAMA"},{"key":"BF1001807_CR45","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0049-3848(98)00099-1","volume":"92","author":"CD Forbes","year":"1998","unstructured":"Forbes CD, for the ESPS Investigators. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamol alone and in combination. Thromb Res 1998; 92: S1\u2013S6.","journal-title":"Thromb Res"},{"issue":"6 Part 1","key":"BF1001807_CR46","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1161\/01.HYP.21.6.875","volume":"21","author":"C Ferri","year":"1993","unstructured":"Ferri C et al. Enhanced blood pressure response to cyclooxygenase inhibition in salt-sensitive human essential hypertension. Hypertension 1993; 21(6 Part 1): 875\u2013881.","journal-title":"Hypertension"},{"key":"BF1001807_CR47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1067\/mhj.2001.111262","volume":"141","author":"LD Fisher","year":"2001","unstructured":"Fisher LD, Gent M, Buller HR . Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001; 141: 26\u201332.","journal-title":"Am Heart J"},{"key":"BF1001807_CR48","first-page":"55","volume":"25","author":"CD Forbes","year":"1999","unstructured":"Forbes CD et al. Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta-blocker and a calcium uptake antagonist. Semin Thromb Hemost 1999; 25: 55\u201360.","journal-title":"Semin Thromb Hemost"},{"key":"BF1001807_CR49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/j.1875-9114.1993.tb02699.x","volume":"13","author":"SA Furey","year":"1993","unstructured":"Furey SA, Vargas R, McMahon FG . Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993; 13: 143\u2013148.","journal-title":"Pharmacotherapy"},{"key":"BF1001807_CR50","doi-asserted-by":"publisher","first-page":"M74","DOI":"10.1093\/gerona\/51A.2.M74","volume":"51","author":"JH Gurwitz","year":"1996","unstructured":"Gurwitz JH et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol A Biol Sci Med Sci 1996; 51: M74\u2013M79.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"BF1001807_CR51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2165\/00002018-199921040-00007","volume":"21","author":"LA Harker","year":"1999","unstructured":"Harker LA, Boissel JP, Pilgrim AJ, Gent M . Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999; 21: 325\u2013335.","journal-title":"Drug Saf"},{"key":"BF1001807_CR52","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S0002-9149(96)00598-X","volume":"78","author":"D Harpaz","year":"1996","unstructured":"Harpaz D et al. Effect of aspirin on the mortality in women with symptomatic or silent myocardial infarction. Am J Cardiol 1996; 78: 1215\u20131219.","journal-title":"Am J Cardiol"},{"key":"BF1001807_CR53","first-page":"494","volume":"45","author":"D Hartmann","year":"1995","unstructured":"Hartmann D et al. Study on the possible interaction between tenoxicam and atenolol in hypertensive patients. Arzneimittelforschung 1995; 45: 494\u2013498.","journal-title":"Arzneimittelforschung"},{"key":"BF1001807_CR54","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/08037059509077612","volume":"4","author":"PJ Harvey","year":"1995","unstructured":"Harvey PJ et al. Effect of indomethacin on blood pressure control during treatment with nitrendipine. Blood Press 1995; 4: 307\u2013312.","journal-title":"Blood Press"},{"key":"BF1001807_CR55","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3109\/07420529709001452","volume":"14","author":"RC Hermida","year":"1997","unstructured":"Hermida RC et al. Influence of aspirin usage on blood pressure: dose and administration-time dependencies. Chronobiol Int 1997; 14: 619\u2013637.","journal-title":"Chronobiol Int"},{"key":"BF1001807_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000115765","volume":"24","author":"E Herskovits","year":"1985","unstructured":"Herskovits E et al. Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants. Eur Neurol 1985; 24: 73\u201381.","journal-title":"Eur Neurol"},{"key":"BF1001807_CR57","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0140-6736(85)91144-4","volume":"1","author":"H Hess","year":"1985","unstructured":"Hess H, Mietaschk A, Deichsel G . Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; 1: 415\u2013419.","journal-title":"Lancet"},{"key":"BF1001807_CR58","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/archinte.1995.00430100075009","volume":"155","author":"MC Houston","year":"1995","unstructured":"Houston MC et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155: 1049\u20131054.","journal-title":"Arch Intern Med"},{"key":"BF1001807_CR59","first-page":"219","volume":"15","author":"AJ Houtsmuller","year":"1984","unstructured":"Houtsmuller AJ et al. The influence of teiclopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 1984; 15: 219\u2013229.","journal-title":"Agents Actions Suppl"},{"key":"BF1001807_CR60","first-page":"257","volume":"10","author":"AG Johnson","year":"1996","unstructured":"Johnson AG et al. Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. J Hum Hypertens 1996; 10: 257\u2013261.","journal-title":"J Hum Hypertens"},{"key":"BF1001807_CR61","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/j.1552-4604.1993.tb01932.x","volume":"33","author":"D Klassen","year":"1993","unstructured":"Klassen D et al. Assessment of blood pressure during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide. J Clin Pharmacol 1993; 33: 971\u2013978.","journal-title":"J Clin Pharmacol"},{"key":"BF1001807_CR62","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/0895-7061(94)00164-7","volume":"8","author":"DK Klassen","year":"1995","unstructured":"Klassen DK, Jane LH, Young DY, Peterson CA . Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. Am J Hypertens 1995; 8: 146\u2013153.","journal-title":"Am J Hypertens"},{"key":"BF1001807_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/01.STR.30.1.1","volume":"30","author":"IM Lee","year":"1999","unstructured":"Lee IM et al. Exercise and risk of stroke in male physicians. Stroke 1999; 30: 1\u20136.","journal-title":"Stroke"},{"key":"BF1001807_CR64","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1212\/WNL.36.5.705","volume":"36","author":"NA Lemak","year":"1986","unstructured":"Lemak NA, Fields WS, Gary Jr HE . Controlled trial of aspirin in cerebral ischemia: an addendum. Neurology 1986; 36: 705\u2013710.","journal-title":"Neurology"},{"key":"BF1001807_CR65","first-page":"S242","volume":"9","author":"A Magagna","year":"1991","unstructured":"Magagna A et al. Indomethacin raises blood pressure in untreated essential hypertensives: a double-blind randomly allocated study versus placebo. J Hypertens Suppl 1991; 9: S242\u2013S243.","journal-title":"J Hypertens Suppl"},{"key":"BF1001807_CR66","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3109\/08037059409102263","volume":"3","author":"A Magagna","year":"1994","unstructured":"Magagna A et al. Hemodynamic and humoral effects of low-dose aspirin in treated and untreated essential hypertensive patients. Blood Press 1994; 3: 236\u2013241.","journal-title":"Blood Press"},{"key":"BF1001807_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199207023270101","volume":"327","author":"AP Maggioni","year":"1992","unstructured":"Maggioni AP et al. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. N Engl J Med 1992; 327: 1\u20136.","journal-title":"N Engl J Med"},{"key":"BF1001807_CR68","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta SR et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527\u2013533.","journal-title":"Lancet"},{"key":"BF1001807_CR69","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1445-5994.1982.tb03826.x","volume":"12","author":"EH Mills","year":"1982","unstructured":"Mills EH, Whitworth JA, Andrews J, Kincaid-Smith P . Non-steroidal anti-inflammatory drugs and blood pressure. Aust N Z J Med 1982; 12: 478\u2013482.","journal-title":"Aust N Z J Med"},{"key":"BF1001807_CR70","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1365-2125.1990.tb03809.x","volume":"30","author":"P Minuz","year":"1990","unstructured":"Minuz P, Barrow SE, Cockcroft JR, Ritter JM . Effects of non-steroidal anti-inflammatory drugs on prostacyclin and thromboxane biosynthesis in patients with mild essential hypertension. Br J Clin Pharmacol 1990; 30: 519\u2013526.","journal-title":"Br J Clin Pharmacol"},{"key":"BF1001807_CR71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2125.1995.tb04408.x","volume":"39","author":"P Minuz","year":"1995","unstructured":"Minuz P et al. Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition. Br J Clin Pharmacol 1995; 39: 45\u201350.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 5","key":"BF1001807_CR72","first-page":"S338","volume":"11","author":"T Morgan","year":"1993","unstructured":"Morgan T, Anderson A . Interaction of indomethacin with felodipine and enalapril. J Hypertens Suppl 1993; 11(Suppl 5): S338\u2013S339.","journal-title":"J Hypertens Suppl"},{"key":"BF1001807_CR73","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S0895-7061(00)01204-8","volume":"13","author":"TO Morgan","year":"2000","unstructured":"Morgan TO, Anderson A, Bertram D . Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000; 13: 1161\u20131167.","journal-title":"Am J Hypertens"},{"issue":"8 Part 1","key":"BF1001807_CR74","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S0895-7061(99)00037-0","volume":"12","author":"JJ Nawarskas","year":"1999","unstructured":"Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA . Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999; 12(8 Part 1): 784\u2013789.","journal-title":"Am J Hypertens"},{"key":"BF1001807_CR75","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0002-9149(98)00153-2","volume":"81","author":"M Oosterga","year":"1998","unstructured":"Oosterga M et al. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol 1998; 81: 1178\u20131181.","journal-title":"Am J Cardiol"},{"key":"BF1001807_CR76","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0952-3278(96)90020-4","volume":"54","author":"P Pancera","year":"1996","unstructured":"Pancera P et al. Changes in peripheral hemodynamics and vasodilating prostaglandins after high-dose short-term ibuprofen in chronically treated hypertensive patients. Prostaglandins Leukot Essent Fatty Acids 1996; 54: 217\u2013222.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"BF1001807_CR77","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","volume":"296","author":"R Peto","year":"1988","unstructured":"Peto R et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313\u2013316.","journal-title":"BMJ"},{"key":"BF1001807_CR78","doi-asserted-by":"crossref","unstructured":"Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129\u2013135.","DOI":"10.1056\/NEJM198907203210301"},{"key":"BF1001807_CR79","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1097\/00004872-199508000-00014","volume":"13","author":"J Polonia","year":"1995","unstructured":"Polonia J et al. Influence of non-steroidal anti-inflammatory drugs on renal function and 24 h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens 1995; 13: 925\u2013931.","journal-title":"J Hypertens"},{"key":"BF1001807_CR80","first-page":"485\u2013492","volume":"15","author":"J Polonia","year":"1996","unstructured":"Polonia J, Gama G, Santos A . [Reduction of the antihypertensive effects of enalapril by indomethacin. Its independence from renal sodium retention]. Rev Port Cardiol 1996; 15: 460, 485\u2013492.","journal-title":"Rev Port Cardiol"},{"key":"BF1001807_CR81","doi-asserted-by":"crossref","unstructured":"Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89\u201395.","DOI":"10.1016\/S0140-6736(00)03539-X"},{"key":"BF1001807_CR82","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1365-2125.1997.00632.x","volume":"44","author":"G Pritchard","year":"1997","unstructured":"Pritchard G et al. Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients? Br J Clin Pharmacol 1997; 44: 145\u2013149.","journal-title":"Br J Clin Pharmacol"},{"key":"BF1001807_CR83","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/1529-0131(200008)43:8<1809::AID-ANR17>3.0.CO;2-D","volume":"43","author":"SM Proudman","year":"2000","unstructured":"Proudman SM et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intra-articular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43: 1809\u20131819.","journal-title":"Arthritis Rheum"},{"key":"BF1001807_CR84","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00005344-199808000-00017","volume":"32","author":"J Puranen","year":"1998","unstructured":"Puranen J, Laakso M, Riekkinen Sr PJ, Sivenius J . Efficacy of antiplatelet treatment in hypertensive patients with TIA or stroke. J Cardiovasc Pharmacol 1998; 32: 291\u2013294.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BF1001807_CR85","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1161\/01.CIR.99.18.2371","volume":"99","author":"KW Mahaffey","year":"1999","unstructured":"Mahaffey KW et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb\/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation 1999; 99: 2371\u20132377.","journal-title":"Circulation"},{"key":"BF1001807_CR86","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/01.STR.32.2.399","volume":"32","author":"P Saloheimo","year":"2001","unstructured":"Saloheimo P, Juvela S, Hillbom M . Use of aspirin, epistaxis and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. Stroke 2001; 32: 399\u2013404.","journal-title":"Stroke"},{"key":"BF1001807_CR87","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/01.CIR.86.5.1407","volume":"86","author":"TL Schreiber","year":"1992","unstructured":"Schreiber TL et al. Randomized trial of thrombolysis versus heparin in unstable angina. Circulation 1992; 86: 1407\u20131414.","journal-title":"Circulation"},{"key":"BF1001807_CR88","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1001\/archneur.1993.00540070030010","volume":"50","author":"J Sivenius","year":"1993","unstructured":"Sivenius J et al. Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event. Arch Neurol 1993; 50: 710\u2013713.","journal-title":"Arch Neurol"},{"key":"BF1001807_CR89","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1681\/ASN.V451133","volume":"4","author":"SR Smith","year":"1993","unstructured":"Smith SR, Coffman TM, Svetkey LP . Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril. J Am Soc Nephrol 1993; 4: 1133\u20131139.","journal-title":"J Am Soc Nephrol"},{"key":"BF1001807_CR90","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/00004872-199408000-00009","volume":"12","author":"ND Sturrock","year":"1994","unstructured":"Sturrock ND, Lang CC, Struthers AD . Indomethacin and cyclosporin together produce marked renal vasoconstriction in humans. J Hypertens 1994; 12: 919\u2013924.","journal-title":"J Hypertens"},{"key":"BF1001807_CR91","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1620\/tjem.165.201","volume":"165","author":"K Takeuchi","year":"1991","unstructured":"Takeuchi K et al. No adverse effect of non-steroidal anti-inflammatory drugs, sulindac and diclofenac sodium, on blood pressure control with a calcium antagonist, nifedipine, in elderly hypertensive patients. Tohoku J Exp Med 1991; 165: 201\u2013208.","journal-title":"Tohoku J Exp Med"},{"issue":"9 Part 1","key":"BF1001807_CR92","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(99)00075-8","volume":"12","author":"V Thakur","year":"1999","unstructured":"Thakur V, Cook ME, Wallin JD . Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal anti-inflammatory drugs. Am J Hypertens 1999; 12(9 Part 1): 925\u2013928.","journal-title":"Am J Hypertens"},{"key":"BF1001807_CR93","first-page":"57","volume":"1","author":"P Tison","year":"1994","unstructured":"Tison P et al. Treatment of hypertension with dihydropyridine calcium antagonists and aspirin. Blood Press Suppl 1994; 1: 57\u201360.","journal-title":"Blood Press Suppl"},{"key":"BF1001807_CR94","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/00004872-200018080-00014","volume":"18","author":"T Tsuji","year":"2000","unstructured":"Tsuji T, Yasu T, Katayama Y, Imanishi M . Different patterns of renal prostaglandins I2 and E2 in patients with essential hypertension with low to normal or high renin activity. J Hypertens 2000; 18: 1091\u20131096.","journal-title":"J Hypertens"},{"key":"BF1001807_CR95","doi-asserted-by":"crossref","unstructured":"UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044\u20131054.","DOI":"10.1136\/jnnp.54.12.1044"},{"key":"BF1001807_CR96","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF01478209","volume":"59","author":"E Walter","year":"1981","unstructured":"Walter E, Kaufmann W, Oster P . Does chronic aspirin treatment increase blood pressure in man? Klin Wochenschr 1981; 59: 297\u2013299.","journal-title":"Klin Wochenschr"},{"key":"BF1001807_CR97","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/00045391-200103000-00003","volume":"8","author":"A Whelton","year":"2001","unstructured":"Whelton A et al. Cyclooxygenase-2\u2014specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85\u201395.","journal-title":"Am J Ther"},{"key":"BF1001807_CR98","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.jhh.1001235","volume":"15","author":"H Celis","year":"2001","unstructured":"Celis H et al. Interaction between nonsteroidal anti-inflammatory drug intake and calcium-channel blocker-based antihypertensive treatment in the Syst-Eur trial. J Hum Hypertens 2001; 15: 613\u2013618.","journal-title":"J Hum Hypertens"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1001807.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001807","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001807.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T07:14:10Z","timestamp":1705821250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1001807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,27]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3,1]]}},"alternative-id":["BF1001807"],"URL":"https:\/\/doi.org\/10.1038\/sj.jhh.1001807","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,27]]},"assertion":[{"value":"18 October 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}